Key result
Circulating miR-197-5P correlated with myocardial fibrosis (r = 0.42, p = 0.008) and was a risk factor for adverse cardiovascular events in heart failure patients under 50 years of age.
Why the study?
Does circulating miR-197-5p correlate with myocardial fibrosis and adverse cardiovascular events in patients with stage C or D heart failure?
Cohort (n=126)
Does circulating miR-197-5p correlate with myocardial fibrosis and adverse cardiovascular events in patients with stage C or D heart failure?
Effect estimate: r = 0.42
p-value: p=0.008
Circulating miR-197-5p may serve as a biomarker for myocardial fibrosis and adverse cardiac events in younger patients (under 50 years) with advanced heart failure.
May support miR-197-5p as fibrosis biomarker in young HF; hypothesis-generating and requires validation before clinical use.
OBJECTIVE: The aim of this study was to identify heart failure (HF)-specific circulating micro-RNAs (miRNA), and examine whether the selected miRNAs correlate with myocardial fibrosis and are reflective of the incidence of adverse cardiovascular events in patients with stage C or D HF. METHODS: Circulating miRNAs which were expressed in end-stage HF patients and matched healthy controls were detected by microarray analysis and validated by quantitative real-time polymerase chain reaction. Multivariate Cox regression analysis was performed to determine whether the selected circulating miRNAs could be prognostic factors in HF patients. RESULTS: In a cohort of 7 healthy controls and 9 patients with stage C or D HF, 7 miRNAs were differentially expressed. These miRNAs were further investigated in a second cohort of 80 patients with stage C or D HF and 30 healthy controls. Only miR-197-5P correlated with fibrosis as seen in cardiac magnetic resonance imaging in patients under the age of 50 years with stage C or D HF (r = 0.42, p = 0.008). Multivariate analyses revealed that miR-197-5P was also a risk factor for composite endpoint events in patients under the age of 50 years with stage C or D HF. CONCLUSION: miR-197-5P is a circulation miRNA that correlates with MF and adverse cardiac events in HF patients under the age of 50 years.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2018) conducted a cohort in Stage C or D Heart Failure (n=126). Circulating miR-197-5p vs. Healthy controls was evaluated on Myocardial fibrosis and composite endpoint events (r = 0.42, p=0.008). Circulating miR-197-5P correlated with myocardial fibrosis (r = 0.42, p = 0.008) and was a risk factor for adverse cardiovascular events in heart failure patients under 50 years of age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: